Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Gains from Sales and Divestitures (2022 - 2023)

Historic Gains from Sales and Divestitures for Ensysce Biosciences (ENSCW) over the last 2 years, with Q3 2023 value amounting to $938.0.

  • Ensysce Biosciences' Gains from Sales and Divestitures fell 9730.98% to $938.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $938.0, marking a year-over-year decrease of 9730.98%. This contributed to the annual value of $41867.0 for FY2022, which is N/A changed from last year.
  • Per Ensysce Biosciences' latest filing, its Gains from Sales and Divestitures stood at $938.0 for Q3 2023, which was down 9730.98% from $312.0 recorded in Q1 2023.
  • In the past 5 years, Ensysce Biosciences' Gains from Sales and Divestitures ranged from a high of $41867.0 in Q4 2022 and a low of $312.0 during Q1 2023